Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra low-dose decitabine ± As4S4 in intermediate-high risk MDS
ChiCTR-IPR-17011619Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) comparing Ultra low-dose decitabine with Ultra low-dose decitabine + As4S4 (2 arms). Primary endpoint: overall response rate. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
decitabinearsenic sulfide
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR-IPR-17011619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011619.